Simultaneous Targeting of CD19 and CD22: Phase I Stud
Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Pat
Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Stu

Blood

132, 279-279

DOI: 10.1182/blood-2018-99-118616

Citation Report

#	Article	IF	Citations
1	Multi-Specific CAR Targeting to Prevent Antigen Escape. Current Hematologic Malignancy Reports, 2019, 14, 451-459.	1.2	13
2	Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. International Journal of Molecular Sciences, 2019, 20, 5010.	1.8	35
3	Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Frontiers in Immunology, 2019, 10, 2664.	2.2	214
4	Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 2019, 25, 1341-1355.	15.2	400
5	Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. Journal of Hematology and Oncology, 2019, 12, 57.	6.9	46
6	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. Journal of Hematology and Oncology, 2019, 12, 17.	6.9	80
7	Mechanisms of and approaches to overcoming resistance to immunotherapy. Hematology American Society of Hematology Education Program, 2019, 2019, 226-232.	0.9	23
8	Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	12
9	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096296.	1.4	7
10	Hodgkin lymphoma. Nature Reviews Disease Primers, 2020, 6, 61.	18.1	103
11	Improving CAR T-cells: The next generation. Seminars in Hematology, 2020, 57, 115-121.	1.8	13
12	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
13	Acute lymphoblastic leukaemia. Lancet, The, 2020, 395, 1146-1162.	6.3	343
14	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. Cancers, 2020, 12, 842.	1.7	21
15	Recent Advances in the Management of Acute Lymphoblastic Leukaemia. Current Treatment Options in Oncology, 2020, 21, 23.	1.3	16
16	State-of-Art of Cellular Therapy for Acute Leukemia. International Journal of Molecular Sciences, 2021, 22, 4590.	1.8	12
17	Updates in Childhood Leukemia. Advances in Oncology, 2021, 1, 169-180.	0.1	0
18	Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder. Frontiers in Oncology, 2021, 11, 709370.	1.3	11

#	Article	IF	Citations
19	CAR T Cells for Hematologic Malignancies. , 2021, , 829-846.		0
20	Beyond the storm â€" subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	12.5	37
21	Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Therapy, 2022, 29, 1080-1096.	2.2	52
22	Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC Cancer, 2022, 22, 98.	1.1	15
23	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
24	Next Generation Natural Killer Cells for Cancer Immunotherapy. Frontiers in Immunology, 2022, 13, .	2.2	14
25	Emerging frontiers in immuno- and gene therapy for cancer. Cytotherapy, 2023, 25, 20-32.	0.3	3
26	CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines, 2023, 11, 165.	2.1	9